Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
08 November 2022 - 12:30AM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused
biopharmaceutical company, today announced the appointment of
Andrea DiFabio as Chief Legal Officer and Corporate Secretary,
effective immediately. Ms. DiFabio will provide strategic
leadership and oversight of the planning and execution for Xenon’s
legal function on a global basis.
Mr. Ian Mortimer, Xenon’s President and Chief
Executive Officer, stated, “We are very pleased to welcome Andrea
to Xenon’s senior leadership team in the newly created role of
Chief Legal Officer. Andrea joins us at a time when we have
multiple late-stage clinical programs underway with the goal of
commercializing new epilepsy therapeutics. She is an inspiring
leader who has previously advised and played a key role in the
approval and launch of several commercial products. She comes to us
with a proven track record in public companies within the life
sciences sector and extensive experience in the neurology space,
and we look forward to benefiting from her strategic counsel.”
Ms. Andrea DiFabio commented, “I am excited to
join Xenon during this important time of growth and late-stage
clinical development. I look forward to acting as a strategic
business partner to the leadership team and contributing to Xenon’s
future successes as we strive to develop new neurology therapeutics
for patients in need.”
Ms. DiFabio is a global pharmaceutical executive
and legal officer with extensive experience in life sciences
companies, including the approval and launch of commercial
products. Prior to joining Xenon, Ms. DiFabio was the Chief Legal
& Administrative Officer and Corporate Secretary at Repertoire
Immune Medicines, Inc. from March 2020 to October 2022, where she
developed broad experience supporting all aspects of the company,
including business and clinical development, investor
communications, risk management, and developing the company’s IP
and communication strategy. From 2019 to 2020, Ms. DiFabio served
as Chief Legal Officer and Corporate Secretary at Codiak
Biosciences, Inc. Prior to its acquisition by Sanofi for $11.6
billion in early 2018, Ms. DiFabio served as Executive Vice
President, Chief Legal Officer and Corporate Secretary at
Bioverativ Inc. from late 2016 to 2018 after playing a key role in
this spinoff company of Biogen Inc. Previously, Ms. DiFabio joined
Biogen in 2006 as Corporate Counsel and was promoted to Vice
President, Chief US Counsel in 2007 and subsequently to various
positions of increasing responsibility, where she was involved in
key strategic transactions, as well as the approval and launch of
numerous neurology products. Prior to her experience at Biogen,
from 1999 to 2006, Ms. DiFabio was a member of the executive team
and senior legal counsel at Parexel International, a publicly
traded clinical research organization. Ms. DiFabio earned a Juris
Doctor degree from Northeastern University School of Law, and a
Bachelor of Arts, Summa Cum Laude from Boston University, where she
also participated in the Executive MBA Program.
About Xenon Pharmaceuticals
Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a
clinical stage biopharmaceutical company committed to developing
innovative therapeutics to improve the lives of patients with
neurological disorders. We are advancing a novel product pipeline
of neurology therapies to address areas of high unmet medical need,
with a focus on epilepsy. For more information, please visit
www.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. These forward-looking
statements are not based on historical fact, and include statements
regarding the timing of and potential results from clinical trials;
our ability to successfully develop and achieve milestones in our
XEN1101 and other development programs; and our ability to
successfully develop and obtain regulatory approval of XEN1101 and
our other product candidates. These forward-looking statements are
based on current assumptions that involve risks, uncertainties and
other factors that may cause the actual results, events, or
developments to be materially different from those expressed or
implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but
are not limited to: clinical trials may not demonstrate safety and
efficacy of any of our or our collaborators’ product candidates;
promising results from pre-clinical development activities or early
clinical trial results may not be replicated in later clinical
trials; our assumptions regarding our planned expenditures and
sufficiency of our cash to fund operations may be incorrect; our
ongoing discovery and pre-clinical efforts may not yield additional
product candidates; any of our or our collaborators’ product
candidates, including XEN1101 may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs;
regulatory agencies may impose additional requirements or delay the
initiation of clinical trials; the impact of competition; the
impact of expanded product development and clinical activities on
operating expenses; the impact of new or changing laws and
regulations; the impact of the ongoing COVID-19 pandemic on our
research and clinical development plans and timelines and results
of operations, including impact on our clinical trial sites,
collaborators, regulatory agencies and related review times, and
contractors who act for or on our behalf, may be more severe and
more prolonged than currently anticipated; the impact of the
COVID-19 pandemic on our business; the impact of unstable economic
conditions in the general domestic and global economic markets;
adverse conditions from geopolitical events; as well as the other
risks identified in our filings with the Securities and Exchange
Commission and the securities commissions in British Columbia,
Alberta, and Ontario. These forward-looking statements speak only
as of the date hereof and we assume no obligation to update these
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi RegtsXenon
Pharmaceuticals Inc.Phone: 604.484.3353Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Mar 2024 to Mar 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Mar 2023 to Mar 2024